IntegraGen SA Obtains Exclusive License for MicroRNA Which Predicts Therapy Outcomes in Metastatic Colorectal Cancer

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EVRY, France--(BUSINESS WIRE)--IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, announced today that it has finalized an agreement providing the company with exclusive licensing rights for the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be a predictor of progression free survival in patients with metastatic colorectal cancer treated with anti-EGFR therapy. This exclusive license is based on original research led by Professor Laurent-Puig, M.D., Ph.D., Professor, Department of Genetics and head of the Clinical Oncogenetic Unit at European Georges Pompidou Hospital University Paris Descartes in Paris, France. IntegraGen obtained the exclusive license for the worldwide rights for this biomarker from the Paris Descartes University, INSERM, the Centre National de la Recherche Scientifique, and the Assistance Publique - Hopitaux de Paris, all leading French academic institutions which, along with IntegraGen, are co-owners of the patent.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC